0001213900-12-000035.txt : 20120105 0001213900-12-000035.hdr.sgml : 20120105 20120105145048 ACCESSION NUMBER: 0001213900-12-000035 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20120105 DATE AS OF CHANGE: 20120105 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: RADIENT PHARMACEUTICALS Corp CENTRAL INDEX KEY: 0000838879 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330413161 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-60019 FILM NUMBER: 12510672 BUSINESS ADDRESS: STREET 1: 2492 WALNUT AVENUE STREET 2: STE 100 CITY: TUSTIN STATE: CA ZIP: 92780 BUSINESS PHONE: 7145054460 MAIL ADDRESS: STREET 1: 2492 WALNUT AVENUE STREET 2: STE 100 CITY: TUSTIN STATE: CA ZIP: 92780 FORMER COMPANY: FORMER CONFORMED NAME: AMDL INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: CALIFORNIA VENTURES INC DATE OF NAME CHANGE: 19890905 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ALPHA CAPITAL ANSTALT CENTRAL INDEX KEY: 0001140358 IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: PRADAFAUT 7 STREET 2: FURSTENTUMS 1490 CITY: VADUZ LIECHTENSTEIN STATE: C4 ZIP: 99999 BUSINESS PHONE: 0114232376363 MAIL ADDRESS: STREET 1: PRADAFAUT 7 STREET 2: FURSTENTUMS 1490 CITY: VADUZ LIECHTENSTEIN STATE: C4 ZIP: 99999 FORMER COMPANY: FORMER CONFORMED NAME: ALPHA CAPITAL AKTIENGESELLSCHAFT DATE OF NAME CHANGE: 20010510 SC 13G/A 1 sc13g0112a2alpha_radient.htm AMENDED SCHEDULE 13G sc13g0112a2alpha_radient.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 2)

 
RADIENT PHARMACEUTICALS CORPORATION
(Name of Issuer)

 
COMMON STOCK, $.001 PAR VALUE
(Title of Class of Securities)
 

750341109
(CUSIP Number)


November 28, 2011
(DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT)

 
Check the appropriate box to designate the rule pursuant to which this Schedule is filed: x Rule 13d-1(c)
 
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 
 
(Continued on following page(s)
 
Page 1 of 4 Pages

 
 
 
 
CUSIP No. 750341109     13G        Page 2 of 4 Pages
 

 1.  NAMES OF REPORTING PERSON
                S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

      Alpha Capital Anstalt
2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:
                                                                 (a)  o
                                                                 (b)  o
3.   SEC USE ONLY
 
 
4.   CITIZENSHIP OR PLACE OF ORGANIZATION

      Liechtenstein
5.   SOLE VOTING POWER, NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON – 30,189,009 Common Stock
 
 
6.   SHARED VOTING POWER - None
 
 
7.   SOLE DISPOSITIVE POWER – 30,189,009 shares of Common Stock
 
 
8.   SHARED DISPOSITIVE POWER - None
 
 
9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON -

      30,189,009 shares of Common Stock
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES   x
 
Pursuant to the terms of the November 28, 2011 agreement modifying the Final Settlement Agreement, the convertibility of the notes issued to Alpha Capital Anstalt, the issuance of Settlement Shares and the convertibility and exercisability of all convertible and exercisable instruments of the Company held by Alpha Capital Anstalt is limited if, upon issuance, conversion or exercise thereof, Alpha Capital Anstalt or any of its affiliates would beneficially own more than 2.9% of the Company’s common stock.
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

      2.9%
12. TYPE OF REPORTING PERSON
 
      CO
  
 
 
 
 
CUSIP No. 750341109     13G        Page 3 of 4 Pages
 
ITEM 1 (a) NAME OF ISSUER: Radient Pharmaceuticals Corporation, a Delaware corporation

ITEM 1 (b) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:

2492 Walnut Avenue, Suite 100, Tustin, CA 92780

ITEM 2 (a) NAME OF PERSON FILING: Alpha Capital Anstalt

ITEM 2 (b) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

Pradafant 7, Furstentums 9490, Vaduz, Liechtenstein

ITEM 2 (c) CITIZENSHIP: Liechtenstein

ITEM 2 (d) TITLE OF CLASS OF SECURITIES: Common Stock, $.001 par value

ITEM 2 (e) CUSIP NUMBER: 750341109

ITEM 3 IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B) OR 13D-2(B):  Not applicable

ITEM 4 OWNERSHIP

         (a) AMOUNT BENEFICIALLY OWNED: 30,189,009 Shares of Common Stock

         (b) PERCENT OF CLASS: 2.9%

         (c) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:

             (i)   SOLE POWER TO VOTE OR DIRECT THE VOTE

30,189,009 Shares

             (ii)  SHARED POWER TO VOTE OR DIRECT THE VOTE

0 Shares

             (iii) SOLE POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

30,189,009 Shares

             (iv) SHARED POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

0 Shares

 
 
 
 
CUSIP No. 750341109     13G        Page 4 of 4 Pages
 
ITEM 5   OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

Alpha Capital Anstalt’s ownership is now below 5%.
 
ITEM 6   OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

Not applicable

ITEM 7   IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

Not applicable

ITEM 8   IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP

Not applicable

ITEM 9   NOTICE OF DISSOLUTION OF GROUP

Not applicable



SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 
  January 5, 2012  
  (Date)  
     
  /s/ Konrad Ackermann  
  (Signature)  
     
  Konrad Ackermann, Director  
  (Name/Title)